Cargando…
Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial
BACKGROUND: Raised serum uric acid (SUA) level is commonly observed in patients with type 2 diabetes mellitus (T2DM) and is associated with increased morbidity and mortality. Sodium-glucose cotransporter 2 inhibitor, a novel oral diabetic drug, might exert a potential hypouricemic effect. We evaluat...
Autores principales: | Hao, Zhaohu, Huang, Xiao, Shao, Hailin, Tian, Fengshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294165/ https://www.ncbi.nlm.nih.gov/pubmed/30587997 http://dx.doi.org/10.2147/TCRM.S186347 |
Ejemplares similares
-
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
por: Kohan, Donald E, et al.
Publicado: (2014) -
The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD
por: Iwata, Yukimasa, et al.
Publicado: (2023) -
A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023) -
The effect of a brown-rice diets on glycemic control and metabolic parameters in prediabetes and type 2 diabetes mellitus: a meta-analysis of randomized controlled trials and controlled clinical trials
por: Abdul Rahim, Anis Farhanah, et al.
Publicado: (2021) -
Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China
por: Zhaohu, Hao, et al.
Publicado: (2022)